Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells.

Abstract

Due to the success of chimeric antigen receptors (CARs) in hematological tumors, CARs are also being studied to treat solid tumors. Improving the ability of CARs to penetrate solid tumor tissues is one of the biggest challenges. As the most malignant cancer of the female reproductive system, the survival rate of ovarian cancer has not been significantly improved by traditional therapy methods; therefore, it is necessary to develop new therapeutic targets and new immunotherapy methods for ovarian cancer. UPAR is a glysocylphosphatidylinositol (GPI) anchoring membrane protein that is differentially expressed in normal tissues and ovarian cancer tissues. It has been shown that uPAR up-regulation promotes tumor development, proliferation, invasion, and metastasis, and uPAR is also up-regulated in tumor matrix components. In our study, CARs were designed using the natural ligand binding fragment of uPAR for ovarian cancer.

• Authors: Liang Wang, Rulin Yang, Liping Zhao, Xiwen Zhang, Tianmin Xu, Manhua Cui
• Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 117 Pg. 109173 (Sep 2019) ISSN: 1950-6007 [Electronic] France
• PMID: 31387176 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Chemical References

• Antineoplastic Agents
• Membrane Proteins
• Receptors, Chimeric Antigen

Topics

• Adult
• Aged
• Antineoplastic Agents (pharmacology)
• Cell Line
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Female
• HEK293 Cells
• Humans
• Immunotherapy (methods)
• Membrane Proteins (metabolism)
• Middle Aged
• Neoplasm Metastasis (drug therapy)
• Ovarian Neoplasms (drug therapy, metabolism, therapy)
• Receptors, Chimeric Antigen (metabolism)
• Up-Regulation (drug effects)
• Young Adult